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SELECTION OF THE MONTH 
Big Title: Non-selective beta blockers IMPROVE survival of ACLF patients 
Small Titles:  
Beyond hNTCP – the missing link to support fully permissive immuno-
competent HBV mouse models 
New Practice guidelines for NAFLD 
A nanoparticle-based therapy to decrease portal pressure 
 
 
ALCOHOLIC LIVER DISEASE (ALD) 
Hepatocytes exposed to alcohol drive inflammation, the proto-oncogene c-myc 
promotes disease initiation and progression 
The mechanisms by which hepatocyte exposure to alcohol results in stimulation of 
resident macrophages (i.e., Kupffer cells) and/or recruitment of monocytes are 
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unknown. Verma et al. were interested in CD40 ligand (CD40L, also known as tumor 
necrosis factor (TNF) ligand superfamily member 5) whose interaction with CD40 
(known as TNF receptor superfamily member 5) triggers the inflammatory NF-
kappaB pathway. They show that when exposed to alcohol, hepatocytes 
overexpressing alcohol-metabolizing enzymes release, in a caspase-dependent 
manner, extracellular vesicles containing CD40L, which can stimulate macrophages 
to produce inflammatory cytokines. These results suggest a new model in which 
hepatocyte injury/stress (the nature of which remaining elusive) promotes 
inflammation by stimulating resident macrophages.  
The proto-oncogene c-myc (encoded by MYC) is a multifunctional, nuclear 
phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular 
transformation. It functions as a transcription factor that regulates transcription of 
specific target genes. The potential role of c-myc in the development of ALD is 
unknown. Here Nevzovora et al. address this question by using mice with transgenic 
expression of c-myc in hepatocytes that received or not alcohol. They find that 
expression of c-myc and alcohol synergistically accelerates the progression of 
ALD presumably due to loss of p53-dependent protection. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Hedgehog signaling, Laminin-332 and cancer stem cells, complete removal of 
tumor-bearing portal territory, blood transfusion (PBT) and HCC resection 
The Hedgehog (Hh) family of secreted signaling proteins plays a crucial role in 
development of diverse animal phyla, from Drosophila to humans, regulating 
morphogenesis of a variety of tissues and organs. Hh signaling is also involved in 
control of stem cell proliferation in adult tissues and aberrant activation of the Hh 
pathway has been linked to multiple types of human cancer. Members of the Hh 
family bind to patched (ptc), thus releasing smoothened (smo) to transduce a signal. 
Transcriptional activation occurs through the GLI family of proteins resulting in 
activation of target genes. There are three human Hh proteins: Sonic hedgehog 
(Shh), Desert hedgehog (Dhh) and Indian hedgehog (Ihh). Little is known on the role 
(Hh signaling in liver fibrosis and HCC. Chung et al. using a transgenic model of Shh 
hepatic expression show that this expression induces liver fibrosis with 
concurrent activation of hepatic stellate cells and fibrogenic genes. It can also 
enhance liver carcinogenesis induced by other oncogenes. 
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Cancer stem cells (CSCs) may persist in tumors due to their chemoresistance and 
cause relapse and metastasis. Govare et al. using elegant approaches in HCC and 
under vivo and in vitro conditions, identify an important role for laminin (Ln)-332 and 
more precisely its γ2-chain as part of the specialized CSC niche in maintaining 
and supporting ‘stemness’. The γ2-chain of Ln-332 could be a novel target in the 
treatment of HCC. 
Although anatomic resection of the tumor-bearing portal territory has been reported 
to be associated with decreased recurrence of HCC, its oncologic advantage is 
controversial. Sindoh et al. address this question in a prospective series of 209 
patients with Child-Pugh class A cirrhosis and solitary HCC of less than 5 cm. They 
show that complete removal of tumor-bearing portal territory decreases risk of 
local recurrence and death from HCC. 
Several studies have reported on the negative effects of perioperative blood 
transfusion (PBT) on oncologic outcomes after curative resection of HCC. However, 
these findings are controversial. To address this issue, Yang et al. report the results 
of a retrospective cohort study including 1103 patients and investigated the 
relationship between PBT and long-term recurrence and survivals after curative 
resection of HCC using propensity score matching and multivariable Cox regression 
analyses. They find no evidence for an influence of PBT on recurrence-free 
survival and overall survival after curative resection of HCC. 
 
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
Molecular and genetic drivers of fibrosis in NASH, a nanoparticle-based 
approach is useful to decrease portal pressure 
The development of liver fibrosis determines the progression to cirrhosis in patients 
with NASH. In this issue, Eguchi et al. studied the role of Bid, a key pro-apoptotic 
molecule(encoded by Bid, for BH3 interacting domain death agonist), in 
experimentally-induced fatty liver in mice. By using different genetic approaches 
including hepatocyte-specific Bid deficient mice, the authors provide convincing 
evidence that Bid participates in fibrosis progression. These findings are consistent 
with existing evidence that hepatocyte apoptosis triggers stellate cells activation 
and liver fibrosis and suggest that Bid inhibition may be useful as an antifibrotic 
therapy in fatty liver diseases. In another article, Petta et al. were interested in 
MERTK (for MER Proto-oncogene, tyrosine Kinase; encoding the protein tyrosine 
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kinase Mer). Mer belongs to the family of TAM (for Tyro, Axl, Mer) receptors that are 
expressed at cell surface of macrophages and dendritic cells and play a role in 
apoptotic cell clearance (and thus tissue homeostasis) and inhibition of Toll-like 
receptor mediated inflammation. Genetic variations in MERTK which is known to 
regulate fibrosis in hepatitis C, are associated with the susceptibility of NASH patients 
to develop fibrosis. Petta et al. studied a large cohort of patients and experimental 
models of NASH. MERTK was overexpressed in the liver of NAFLD patients with F2-
F4 fibrosis and in models of fibrogenesis and induce fibrogenic actions in stellate 
cells. Moreover, they demonstrated that the rs4374383 AA genotype, associated 
with lower intrahepatic expression of MERTK, is protective against F2-F4 fibrosis 
in patients with NAFLD.  
In a third study, Oro et al. studied the beneficial effects of cerium oxide nanoparticles 
(CeO2NPs), a new pharmacological tool with potential antioxidant and anti-
inflammatory properties. Systemic and hepatic effects were assessed in CCl4-treated 
rats receiving nanoparticles or vehicle. Most CeO2NPs were located in the liver and 
reduced hepatic steatosis, systemic and hepatic inflammatory biomarkers and 
portal pressure without affecting mean arterial pressure. This novel approach may 
be of therapeutic value in advanced liver diseases and clinical trials are anticipated. 
 
HEPATITIS B 
Silencing hepatitis B virus (HBV) RNA, restoration of HBV specific T-cell 
response by combination therapy, beyond hNTCP – the missing link to support 
fully permissive immunocompetent HBV mouse models 
The limitations of current licensed HBV oral drugs – the nucleos(t)ide analogs - are 
their rather limited effect on HBsAg production because HBV mRNAs derived from 
the nuclear cccDNA are continuously produced even under effective suppression of 
viral replication. Yamamoto et al. provide a novel and very sophisticated approach by 
developing short-interfering RNAs (siRNAs) targeting these HBV-specific RNAs in 
order to suppress production of HBV proteins. Hepatocyte specific delivery of the 
siRNA - one of the most challenging issues in silencing strategies - was realized by 
designing a novel pH-sensitive hepatocyte-specific multifunctional envelope-type 
nanodevice drug delivery system (MEND/HBV-siRNAmix). MEND/HBV-siRNA 
caused a significantly more efficient reduction of HBsAg and HBeAg in primary 
human hepatocytes and in chimeric mice with humanized liver as compared to 
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entecavir; and quite interestingly, the effect of a single nanodevice siRNA application 
lasted for two weeks making the MEND/HBV-siRNA an attractive and promising 
novel HBV antiviral candidate. 
Multispecific HBV-specific T cell responses play an important role in acute, self-
limiting HBV infection. T-cell exhaustion, in contrary, has been linked to the chronic 
stage, and is probably the result of repetitive T-cell receptor stimulation by 
persistently high HBV antigen levels. De Niet et al. performed extensive T-cell 
analyses in patients with partially controlled HBV infection (i.e. low-level HBV 
replication) but also patients with high HBV replication who have been treated with a 
combination of peginterferon plus adefovir. A relatively narrow HBV-core-specific T 
cell population with a resting effector-memory phenotype and strong proliferative 
potential, seem to be sufficient to retain the virus at low levels. Whereas a partial 
recovery of HBV-specific T cells showing a broader repertoire was found in 
treatment induced HBsAg loss, as well as in some patients on long-term 
nucleos(t)ide therapy. These data are important for a better understanding of the 
mechanisms behind T-cell dysfunction and treatment-induced restoration, and may 
also foster development of combination therapy strategies to enhance viral 
clearance. 
The discovery of the hNTCP receptor as the main HBV entry receptor opened the 
avenue to establish new HBV replication models by rendering non-permissive cells 
permissive to HBV by the expression of hNTCP. The ability of heterokaryonic cells, 
generated by fusion of hNTCP-expressing mouse and human cell lines with 
replication-supporting but non-infectable HepG2, to fully support HBV replication was 
studied in a very elegant study by Lempp FA et al. The key finding were that first 
despite hNTCP-expression the HBV replication was still restricted in mouse 
cell lines and the nonhepatic human HeLa cells, but second these NTCP-
independent restrictions of HBV infection can be overcome by cell fusion mediated 
complementation with an intracellular factor expressed in HepG2 cells. Identification 
of this missing link will be a major milestone on the way towards the development of 
an immunocompetent mouse model for HBV infections. 
 
HEPATITIS E 
New stem-cell derived hepatitis E virus (HEV) replication model 
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Relatively little is known about the molecular biology of HEV infection and replication 
as in vitro HEV culture systems have only recently been established. The mostly 
transformed cell lines that are used so far, like hepatoma cell lines Huh7, HepG2, 
HepaRG, and others are, however, physiologically less relevant to study HEV 
replication than primary hepatocytes, which are however not readily available. Helsen 
et al. reported now for the first time, the infection of human pluripotent stem 
cell-derived hepatocytes by HEV supporting the complete viral replication 
cycle, and propose this model as an alternative and physiological cell culture model 
for the study of HEV infection and inhibition thereof by antiviral drugs. The new stem 
cell-derived HEV replication model represents an important tool for the future 
investigation of HEV cell tropism and designing novel therapeutic strategies. 
 
CIRRHOSIS 
Non-selective beta-blockers (NSBBs) improve the survival of ACLF patients 
NSBB’s have been the mainstay of pharmacological therapy for portal hypertension 
in cirrhotic patients for over 25 years. Data in the past few years have indicated that 
mortality of patients with refractory ascites or spontaneous bacterial peritonitis may 
be increased if NSBBs are continued. The important paper by Mookerjee et al. 
analyses the data obtained in the prospective observational study in patients with 
acute deterioration of cirrhosis requiring hospital admission, the CANONIC study. 
The results show that the patients that were being treated with NSBBs at the time 
of hospital admission with ACLF had a significantly lower mortality, which was 
associated with less severe inflammatory response. However, the doses of 
NSBBs used was relatively low suggesting that the protective effect may be due to 
mechanisms other than its known hemodynamic effects. The data argue against 
stopping NSBBs in cirrhotic patients unless there are specific contraindications. 
 
PRIMARY SCLEROSING CHOLANGITIS 
Inhibition of bile acid absorption reduces severity of bile duct injury in a mouse 
model 
In the MDR-/- mouse, features of sclerosing cholangitis are known to be associated 
with altered bile acid composition, which after biliary excretion undergoes 
enterohepatic circulation and over 95% is reabsorbed in gut. As these toxic bile acid 
can result in further bile duct injury, reduction in their reabsorption can prevent further 
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bile duct injury. Trauner et al. hypothesized that blocking the ASBT/SLC10A2 
receptor, which is known to take up about 95% BA’s from the gut would prevent bile 
duct injury. The authors used A4250, a specific ASBT inhibitor and showed 
clearly that its use was associated with significant attenuation in the severity of 
bile duct injury providing exciting new data that can potentially be translated 
into clinical practice.  
 
